Regenera set to begin Singapore trials

By Melissa Trudinger
Tuesday, 03 August, 2004

Regenera (ASX: RGA) has received ethics committee approval to begin Phase III human clinical trials for its synthetic steroid drug Visagen at the Singapore Eye Research Institute.

The initial trial will test the treatment on cystoid macular oedema, and the company plans to expand the study with trials evaluating the therapy in age related macular degeneration, uveitis, diabetic macular oedema and as a co-treatment with photodynamic therapy.

Related News

Giving rotavirus vaccine at birth benefits gut bacteria

Babies who receive a RV3-BB rotavirus vaccine at birth appear to show higher levels of good...

TGA approves donanemab for treatment of early Alzheimer's

The TGA has approved the first amyloid-targeting therapy for people with Alzheimer's in...

Ultra-processed foods linked to poor health, premature death

Evidence suggests a dose-response relationship between ultra-processed food consumption and...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd